Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Top Cited Papers
- 4 September 2016
- journal article
- research article
- Published by Elsevier in The Lancet Respiratory Medicine
- Vol. 4 (10) , 781-796
- https://doi.org/10.1016/s2213-2600(16)30265-x
Abstract
No abstract availableKeywords
Funding Information
- F. Hoffmann-La Roche
This publication has 31 references indexed in Scilit:
- Structural Basis of Signaling Blockade by Anti-IL-13 Antibody LebrikizumabJournal of Molecular Biology, 2013
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- Roles of epithelial cell-derived periostin in TGF-β activation, collagen production, and collagen gel elasticity in asthmaProceedings of the National Academy of Sciences, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProceedings of the National Academy of Sciences, 2007
- The reclassification of asthma based on subphenotypesCurrent Opinion in Allergy and Clinical Immunology, 2007
- Determining asthma treatment by monitoring sputum cell counts: effect on exacerbationsEuropean Respiratory Journal, 2006
- IL-13 induces eosinophil recruitment into the lung by an IL-5– and eotaxin-dependent mechanismJournal of Allergy and Clinical Immunology, 2001
- Interleukin-13 but Not Interleukin-4 Prolongs Eosinophil Survival and Induces Eosinophil Chemotaxis.Internal Medicine, 1997
- Dynamic balanced randomization for clinical trialsStatistics in Medicine, 1993